PEDIATRICS Vol. 43 No. 1 January 1969, pp. 26-33
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Honig, G. R.
Right arrow Articles by Schulman, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Honig, G. R.
Right arrow Articles by Schulman, I.

ADMINISTRATION OF SINGLE DOSES OF AHF (FACTOR VIII) CONCENTRATES IN THE TREATMENT OF HEMOPHILIC HEMARTHROSES

George R. Honig M.D.1, Edwin N. Forman M.D.1, Christine A. Johnston M.D.1, Ruth A. Seeler M.D.1, Charles F. Abildgaard M.D.1, and Irving Schulman M.D.1

1 Department of Pediatrics, University of Illinois College of Medicine, Chicago

In the treatment of acute hemarthroses in AHF (factor VIII)-deficient patients it has been our practice to administer repeated infusions of plasma in order to maintain hemostatic levels of AHF over a 48-hour period. In the present study AHF concentrates were administered so as to provide the entire therapeutic AHF replacement in a single infusion. Fifty-one episodes of acute hemarthrosis in 14 boys with AHF deficiency were treated with plasma cryoprecipitate, glycine-precipitated factor VIII (Hyland), or a new higher potency AHF concentrate (Hyland Method 4). Single doses of 20 to 30 units of AHF activity per kilogram were given; this was sufficient to produce a post-infusion AHF level of 40 to 50%. In 47 of the 51 episodes treated, satisfactory resolution of the hemarthroses occurred without need for further AHF therapy. These results appeared at least as satisfactory as those using repeated plasma infusions. Advantages of therapy using single infusions of AHF concentrates include fewer venipunctures, ease of administration, less need for hospitalization, and greater patient acceptance. Studies of Hyland Method 4 AHF concentrate indicated that the dose-response relationship and survival of AHF activity in vivo are similar to that seen with other therapeutic forms of AHF.

Submitted on April 24, 1968
Accepted on July 24, 1968